Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2017-03-31, filed 2017-05-15, with 37 holding rows worth $503,510,000.

Accession
0000930413-17-002121
Filed
2017-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2017

A holdings report, 39 entries on the cover page, a total value of $503,510,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $503,510,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ADAMAS PHARMACEUTICALS INC00548A106COM2,601,351$45,524,000thousands by filing date
CONCERT PHARMACEUTICALS INC206022105COM2,200,000$37,532,000thousands by filing date
SYNERGY PHARMACEUTICALS DEL871639308COM NEW7,223,509$33,662,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM2,232,238$31,251,000thousands by filing date
RIGEL PHARMACEUTICALS INC766559603COMMON STOCK9,105,691$30,140,000thousands by filing date
ZOGENIX INC.98978L204Common Stock2,440,959$26,484,000thousands by filing date
IGNYTA INC451731103COM3,071,300$26,413,000thousands by filing date
THERAPEUTICSMD INC88338N107COM3,460,225$24,914,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM560,000$24,248,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM301,809$21,450,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM300,000$21,321,000thousands by filing dateput
FOAMIX PHARMACEUTICALS LTDM46135105SHS3,681,708$18,224,000thousands by filing date
DBV TECHNOLOGIES S A23306J101ADR485,915$17,114,000thousands by filing date
AVEXIS INC05366U100COM200,000$15,206,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM1,468,521$14,450,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock250,000$12,813,000thousands by filing datecall
GLOBAL BLOOD THERAPEUTICS USD37890U108COM300,000$11,055,000thousands by filing date
PARATEK PHARMACEUTICALS INC699374302Equity539,571$10,387,000thousands by filing date
ACORDA THERAPEUTICS INC00484M106COM432,500$9,083,000thousands by filing dateput
NEURODERM LTDM74231107ORD SHS314,724$8,356,000thousands by filing date
BOVIE MEDICAL CORP10211F100COM3,055,000$8,157,000thousands by filing date
ACCELERON PHARMA INC00434H108COM300,000$7,941,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock1,000,000$7,340,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM1,537,873$6,305,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock155,265$5,613,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM122,129$4,884,000thousands by filing date
MYOVANT SCIENCES LTDG637AM102COMMON STOCK-FO407,559$4,785,000thousands by filing date
CONNECTURE INC COM20786J106Stock4,127,232$4,416,000thousands by filing date
JAZZ PHARMACEUTICALS PLC SHS USDG50871105Stock25,000$3,628,000thousands by filing date
AIMMUNE THERAPEUTICS INC.00900T107Common Stock122,455$2,661,000thousands by filing date
RADIUS HEALTH INC750469207COM NEW50,000$1,933,000thousands by filing dateput
ACORDA THERAPEUTICS INC00484M106COM80,000$1,680,000thousands by filing datecall
CASCADIAN THERAPEUTICS INC14740B606COM NEW377,900$1,565,000thousands by filing date
TREVENA INC89532E109COM338,292$1,242,000thousands by filing date
ARADIGM CORP038505400COM NO PAR NEW637,279$988,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock11,517$590,000thousands by filing date
STREAMLINE HEALTH SOLUTIONS86323X106COM151,611$155,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000930413-17-002121this filing2017-05-15acceptance time not in the bulk data set